45 articles in this topic
A clinical account of the nutrient-sensing trade-off — what actually induces cellular clean-up in humans rather than in mice, why muscle wins the argument in an older patient, and where the rapamycin and metformin evidence genuinely stops.
A clinical guide to protein and metabolite measurement — why these layers report present state rather than inherited risk, what broad panels can and cannot support, and how to judge an organ-age or metabolomic result you did not order.
A deep mechanistic investigation into how rapamycin and next-generation rapalogs modulate aging pathways — from allosteric binding kinetics to clinical trial design and emerging bi-steric inhibitors.
A clinical guide to interpreting biological-age and pace-of-aging results: what the epigenome is, what each generation of clock was trained to predict, why repeat testing of the same sample can differ by years, and how to counsel a patient who wants to buy one.
The fourth-tier hallmarks — regenerative decline, altered tissue signaling, inflammaging and gut dysbiosis — are the ones that actually walk into clinic. How to measure them with a dynamometer, a hallway and a short lab panel, and which single prescription moves several at once.
The three aging processes that begin as protective responses and become drivers — what can actually be measured in clinic today, and where the human evidence for rapamycin, metformin, NAD precursors and senolytics genuinely stands.
A clinical read of the five upstream hallmarks — genomic instability, telomere attrition, epigenetic drift, loss of proteostasis and disabled autophagy — separating what is measurable in a patient from what is mechanism only, and what has human endpoint data from what does not.
A sequenced account of the advanced longevity workup — genome, blood, imaging, function, microbiome, proteomics, liquid biopsy — with a stated confidence on every element and a method for turning fifty abnormal values into one first action.
Explore the advanced molecular architecture of purinergic stress signaling — from transcriptional reprogramming and metabolic crosstalk to emerging therapeutic strategies targeting CD38, P2X7, and the ectonucleotidase axis in aging.
A clinical guide to what common single-nucleotide variants and curated panels genuinely deliver — pharmacogenomic phenotypes, HLA risk types, polygenic percentiles — and the structural reasons a negative panel in a symptomatic patient tells you almost nothing.
A clinician's guide to interpreting metabolizer phenotype labels, the gene–drug pairs with evidence strong enough to act on today, and why a genotype describes capacity rather than current enzyme activity.
A clinician's guide to reading the classification column on a genomic report: what dbSNP, gnomAD and ClinVar each contribute, why a variant of uncertain significance must never drive management, and how to explain penetrance to a patient who has just been called 'pathogenic'.
